Segment Information (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ending June 30, 2025 and 2024 is as follows:

	Three Months Ended June 30, 2025
	Cell Therapy			BioBanking		Degenerative Disease			Other			Total
Net revenues	$	759			1,275		3,702			—			5,736
Cost of revenues (excluding amortization of acquired intangible assets)		—			220		5,022			—			5,242
Direct expenses		2,927			387		1,854			10,818			15,986
Segment contribution	$	(2,168	)	$	668	$	(3,174	)	$	(10,818	)	$	(15,492	)
Indirect expenses										372	(a)		372
Loss from operations													(15,864	)
(a) Components of other
Amortization										372
Total other									$	372

	Three Months Ended June 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other			Total
Net revenues	$	—			1,278		10,833		—			12,111
Cost of revenues (excluding amortization of acquired intangible assets)		—			537		1,586		—			2,123
Direct expenses		3,422			447		5,784		10,054			19,707
Segment contribution	$	(3,422	)	$	294	$	3,463	$	(10,054	)	$	(9,719	)
Indirect expenses									456	(a)		456
Loss from operations												(10,175	)
(a) Components of other
Amortization									456
Total other								$	456

Financial information by segment for the six months ended June 30, 2025 and 2024 is as follows:

	Six Months Ended June 30, 2025
	Cell Therapy			BioBanking		Degenerative Disease			Other			Total
Net revenues	$	1,023			2,683		13,456			—			17,162
Cost of revenues (excluding amortization of acquired intangible assets)		—			429		8,367			—			8,796
Direct expenses		6,184			756		6,601			20,435			33,976
Segment contribution	$	(5,161	)	$	1,498	$	(1,512	)	$	(20,435	)	$	(25,610	)
Indirect expenses										740	(a)		740
Loss from operations													(26,350	)
(a) Components of other
Amortization										740
Total other									$	740

	Six Months Ended June 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other			Total
Net revenues	$	—			2,565		24,227		—			26,792
Cost of revenues (excluding amortization of acquired intangible assets)		—			714		3,049		—			3,763
Direct expenses		8,887			863		10,198		19,630			39,578
Segment contribution	$	(8,887	)	$	988	$	10,980	$	(19,630	)	$	(16,549	)
Indirect expenses									1,002	(a)		1,002
Loss from operations												(17,551	)
(a) Components of other
Amortization									1,002
Total other								$	1,002